Evidence map›Paper›PMID 39852549›Full record

ArticleMarine drugs2025

Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways.

Jing Huang, Lei Li, Liyan Xu, Lixin Feng, Yuxin Wang, Attila Gabor Sik, Meng Jin, Rongchun Wang, Kechun Liu, Xiaobin Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jing HuangBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.
Lei LiBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.ORCID 0009-0003-4619-2319
Liyan XuBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.
Lixin FengBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.
Yuxin WangBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.
Attila Gabor SikBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.ORCID 0000-0001-5572-2156
Meng JinBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.ORCID 0000-0002-1525-0876
Rongchun WangBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.ORCID 0000-0001-6871-5166
Kechun LiuBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.
Xiaobin LiBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.ORCID 0000-0002-3775-7694

Funding

High-tech SMEs Innovation Capacity Improvement Project of Shandong Province 2023TSGC0242, 2024TSGC0145Key R&D Program of Shandong Province 2022CXGC020515Taishan Scholars Program TSQN202312233the Jinan Talent Project for Universities 2021GXRC106, 2021GXRC111, 2021GXRC047the National Natural Science Foundation of China U2006204
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is characterized by uncontrolled, chronic relapsing inflammation in the gastrointestinal tract and has become a global healthcare problem. Here, we aimed to illustrate the anti-inflammatory activity and the underlying mechanism of methyl 3-bromo-4,5-dihydroxybenzoate (MBD), a compound derived from marine organisms, especially in IBD, using a zebrafish model. The results indicated that MBD could inhibit the inflammatory responses induced by CuSO

Indexed as

Anti-Inflammatory AgentsHydroxybenzoatesInflammatory Bowel DiseasesNF-kappa BToll-Like ReceptorsAnimalsAquatic OrganismsDisease Models, AnimalMolecular Docking SimulationSignal TransductionTrinitrobenzenesulfonic AcidZebrafishAnti-Inflammatory AgentsHydroxybenzoatesNF-kappa BToll-Like ReceptorsTrinitrobenzenesulfonic Acidinflammatory bowel diseasemethyl 3-bromo-4,5-dihydroxybenzoateNF-κB pathwayTNBSzebrafish

Identifiers

PMID39852549
PMCPMC11766471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.